Financial Data and Key Metrics Changes - In Q1 2025, the company achieved the highest first quarter lithium sales volumes in its history, with a 20% year-on-year increase, driven by strong demand from the electric vehicle market in China and Europe [6][8] - Average realized prices for lithium in Q2 2025 are expected to be lower than in Q1 due to recent price declines [7][59] Business Line Data and Key Metrics Changes - Lithium sales volumes increased significantly, while iodine prices reached record averages amid tight supply and steady demand, particularly for X-ray contrast media applications [6][8] - Specialty Plant Nutrition (SPN) sales volumes grew healthily, with an upward trend in prices due to strong demand for potassium chloride and supply disruptions [9] - Potassium business volumes were significantly lower compared to the same period last year as part of a strategy to prioritize high lithium content brines [10] Market Data and Key Metrics Changes - The company maintains a view that global lithium demand will grow by 17% in 2025, with SQM's sales expected to grow by 15% year-on-year, although this forecast remains unchanged amid current market conditions [29][64] - The lithium market is currently oversupplied, with prices under pressure, particularly in China [71][90] Company Strategy and Development Direction - The company is focused on expanding lithium production capacity to 240,000 metric tons of lithium carbonate and 100,000 metric tons of lithium hydroxide [8] - Investment in operational efficiencies and capacity expansions is ongoing, with a commitment to sustainable high-quality growth [11] - The company is confident in its strategy and ability to generate cash flow despite current pricing pressures [17][88] Management's Comments on Operating Environment and Future Outlook - Management believes the current low price environment is unsustainable and expects prices to improve in the future [88][90] - The company is well-prepared to take advantage of market recovery due to its strong position as a low-cost producer [88][90] - There is optimism regarding long-term demand growth, particularly in the electric vehicle sector [64][90] Other Important Information - The company is advancing its seawater pipeline construction to expand iodine production capacity [8] - The dividend policy established a distribution of 30% of net income for 2025, with no interim dividends planned for the first quarter [48] Q&A Session Summary Question: Will operating cash flow be breakeven or positive per metric ton in lithium in Q2? - Management indicated they are far from breakeven costs and expect to be significantly above that in Q2 [14][15] Question: How will lower lithium prices affect capital structure and funding for future projects? - Management stated that the company has a strong balance sheet and cash generation capacity from other business lines, which will not constrain future projects [16][18] Question: What is the status of the Codelco joint venture in Chile? - Management described the situation as "noise" due to election year discussions but confirmed that the transaction is progressing as planned [20][26] Question: Will SQM's lithium sales grow by 15% this year? - Management has not updated the annual volume forecast but expects similar or slightly lower volumes in Q2 compared to Q1 [29] Question: How is SQM handling pricing dynamics in China? - Management noted that pricing mechanisms with customers are confidential and cannot provide specifics [36] Question: What is the outlook for Mt. Holland production? - Management confirmed that Mt. Holland is cash positive and ramping up as planned, despite facing higher costs during the ramp-up phase [84][97] Question: What is the company's dividend policy? - The company will distribute 30% of its net income for 2025, with no interim dividends planned for the first quarter [48]

2025年5月20-22日,备受全球营养健康行业瞩目的 Vitafoods Europe 2025 展会在西班牙巴塞罗那盛大召 开。历经27 年锤炼，Vitafoods Europe已发展成为欧洲营养保健品和原料行业最大的专业展会。为保健 品、功能性食品、运动营养、营养美容品行业的原料、配料、成品、生产技术、咨询服务等优秀企业构 建了一个市场开拓、技术交流的全产业链平台，成为欧洲乃至全球营养健康产业的盛会，Vitafoods Europe的举办，意味着全球健康营养行业开启加速发展新篇章。 今年，展会汇聚了超过 1300 家参展商和来自 110 多个国家的 20000 多名观众，共同探讨营养健康产业 的未来发展趋势。作为美国运动营养领先品牌代表，KORI受邀参会，与全球优秀健康品牌共话未来健 康。 美国KORI以海洋生物科技革新运动营养产业 源自纽约运动健康实验室的KORI，秉持"南极能量，自然出色"的品牌主张，专注将南极磷虾天然活性 成分与前沿生物技术融合，研发符合运动人群需求的精准营养体系，为现代都市人提供活力支持。 KORI与挪威AKER等全球优质供应商建立了长期稳定的合作关系，并且接受MSC等国际权威检 ...

Core Insights - Edible Garden AG Incorporated has launched its Kick. Sports Nutrition product line on Amazon, marking a significant step in its strategy to strengthen its Farm to Formula® positioning and expand into the 'Better for You' consumer products market [1][2] - The global sports nutrition market is projected to grow from $54.8 billion in 2023 to $103.3 billion by 2032, indicating a substantial opportunity for innovation and accessibility in this sector [5] Company Overview - Edible Garden is a leader in controlled environment agriculture (CEA), focusing on locally grown, organic, and sustainable produce, and operates state-of-the-art vertically integrated greenhouses and processing facilities in New Jersey and Michigan [7] - The company has developed a range of products, including plant-based and whey protein powders under the Vitamin Way® and Vitamin Whey® brands, and is committed to sustainability through initiatives like Walmart's Project Gigaton [7] Product Launch Details - The Kick. Sports Nutrition line features clean-label, functional formulas designed for athletes, with an initial offering of plant-based and whey protein powders, and plans for a full range of pre-workout, post-workout, and hydration products [3][4] - The partnership with Pirawna, an e-commerce growth agency, aims to ensure a successful entry into the competitive sports nutrition market by leveraging their expertise in scaling brands on Amazon [4] Market Context - The launch of Kick. Sports Nutrition aligns with rising health awareness and a growing emphasis on fitness and active lifestyles, positioning the company to meet the evolving demands of today's health-conscious consumers [5]

Core Insights - HBC reported total operating revenues of NOK 60.9 million in Q1 2025, a 15% increase from NOK 52.4 million in Q1 2024, driven by growth in higher-margin human and pet health segments despite production constraints and commodity oil market pressures [1][6] - The company experienced a significant increase in B2B sales in the human segment, with a 66% year-over-year growth, particularly for products like OmeGo® and ProGo® [6] - HBC launched an unsecured bond that closed after the quarter with subscriptions of approximately CHF 3.5 million, indicating strong investor interest [6] Financial Performance - Cost of goods sold (CoGS) rose to NOK 37.5 million from NOK 27.3 million in Q1 2024, while operating expenses slightly decreased to NOK 23.1 million from NOK 23.9 million [2] - EBITDA for the quarter was negative NOK 19.9 million, compared to NOK -16.2 million in Q1 2024, with operational EBITDA at NOK -8.3 million [3] - The first quarter included NOK 3.0 million in one-time restructuring costs aimed at improving long-term operational efficiency [2][3] Product and Market Developments - HBC's product offerings include ProGo®, OmeGo®, and CalGo® / NT-II®, which are designed to enhance human and pet health [5] - The company achieved a record production period at its Midsund facility, operating 15-20% above its rated capacity while maintaining quality [6] - Clinical studies have shown that OmeGo® significantly reduces coughing and improves sleep in individuals exposed to pollution, while NT-II™ demonstrated improvements in joint pain and stiffness [6][7] Strategic Initiatives - HBC is expanding its production capacity at Berkåk to triple output, reflecting confidence in future demand [6] - The company has made significant advances in pharmaceutical research, including programs targeting prostate cancer and asthma, and has established a biotech-focused spin-off, HBC Immunology [7] - HBC participated in major industry events, reinforcing its leadership in marine-based nutrition and expanding its market presence [6]

Financial Data and Key Metrics Changes - Revenue for Q1 2025 increased by 47% year-over-year to $7,900,000, exceeding guidance of $7,800,000, driven by balanced growth in the Vinia business [5][20] - Gross profit rose by 53% to $4,600,000, representing 58.5% of total revenue, up from 56.2% a year ago, primarily due to increased manufacturing scale and improved yield [20][21] - Net loss for Q1 2025 was $2,300,000, or $0.13 per share, compared to a net loss of $6,600,000, or $0.48 per share in the same quarter last year [21][22] Business Line Data and Key Metrics Changes - The Direct to Consumer Health and Wellness Products Division, led by Vinia, accounted for the majority of revenue, with total active subscribers exceeding 50,000 in the USA, and recurring subscribers making up 90% of revenue [6][13] - The Amazon channel represented 20% of the business, with improvements in customer conversion and repeat purchase rates [6] - The company launched new products, including a superfood tea lineup and plans for a hydration beverage, targeting significant market segments [9][12][60] Market Data and Key Metrics Changes - The company is expanding its reach into new consumer segments and channels, including international shipping and social media platforms like TikTok [42][43] - The market for non-GMO, plant-based compounds is growing, with increasing consumer awareness of health benefits related to blood flow and longevity [8][79] Company Strategy and Development Direction - The company aims to achieve adjusted EBITDA breakeven at $11,000,000 to $12,000,000 in quarterly revenue by the second half of 2025, focusing on balancing growth with profitability [17][18] - Strategic investments will be made in expanding the direct-to-consumer portfolio, enhancing R&D processes, and building AI-powered tools for CDMO services [18] - The company is targeting a 20% adjusted EBITDA margin for its direct-to-consumer division and higher margins in the CDMO segment [18] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's ability to execute its growth strategy and deliver life-changing compounds, highlighting the synergy between the direct-to-consumer and CDMO divisions [23][70] - The company is optimistic about the increasing interest from pharmaceutical companies in its botanical synthesis technology, which offers consistent and economically viable compounds [70][71] Other Important Information - The company raised $3,900,000 in debt financing during the quarter, increasing cash and cash equivalents to $3,400,000 [22] - The company is preparing to launch the olivoboscoside cell product in 2026, targeting significant market opportunities in liver health and cholesterol management [13][79] Q&A Session Summary Question: Can you provide details on the Phase two portion of the CDMO contract? - Management explained that Phase two involves moving from solid media to liquid media for cell conditioning, with an expected timeline of six to nine months [27][28] Question: How long will it take to narrow down targets with Tate and Lyle? - Management indicated that significant work is underway, with a comprehensive update expected by the end of the year [30] Question: Should we expect continued gross margin expansion as revenue grows? - Management affirmed the intention to drive continued gross profit margin improvement alongside revenue growth [31][32] Question: How many products contributed to revenue in Q1, and how many are expected by year-end? - Management noted that three product lines contributed to Q1 revenue, with expectations to increase to four by Q2 and five by Q3 or Q4 [36][38] Question: Will marketing costs drop due to increased ad inventory? - Management highlighted efforts to reduce marketing costs as a percentage of revenue while exploring new channels for customer acquisition [39][44] Question: Does the second quarter guidance include contributions from the CDMO business? - Management confirmed that the guidance includes revenue recognition from existing CDMO projects and potential new catalysts [45][46] Question: How many CDMO programs can be run concurrently? - Management stated that the current capacity allows for five to seven concurrent projects in stage one [49] Question: What is the long-term opportunity for the beauty product? - Management discussed a focused strategy on high-margin categories, including health and beauty, with plans for a launch in Q1 next year [60][61]

OMAHA, NE, May 15, 2025 (GLOBE NEWSWIRE) -- FitLife Brands, Inc. (“FitLife” or the “Company”) (NASDAQ: FTLF), a provider of innovative and proprietary nutritional supplements and wellness products, today announced financial results for the first quarter ended March 31, 2025. Highlights for the first quarter ended March 31, 2025 include: Total revenue was $15.9 million, 4% lower than the first quarter of 2024. Online sales were $10.6 million, representing 67% of total revenue and down 2% compared to the firs ...

The Beachbody Company (BODI) Q1 2025 Earnings Call May 14, 2025 05:00 PM ET Company Participants Bruce Williams - Managing DirectorMark Goldston - Executive ChairmanCarl Daikeler - Co-Founder, Chairman and CEOBrad Ramberg - Interim Chief Financial OfficerAlec Legg - Vice President , Equity Research Conference Call Participants George Kelly - Managing Director, Senior Research AnalystChristopher Sakai - Analyst Operator Good afternoon. Thank you for attending today's Beachbody Company Inc. First Quarter twen ...

The Beachbody Company (BODI) Q1 2025 Earnings Call May 14, 2025 05:00 PM ET Speaker0 Good afternoon. Thank you for attending today's Beachbody Company Inc. First Quarter twenty twenty five Earnings Conference Call. My name is Victoria, and I will be your moderator for today's call. All lines will be muted during the presentation portion of the call with the opportunity for questions I would now like to pass the conference over to your host, Bruce Williams, Managing Director of ICR. You may proceed, Bruce. S ...

CARLSBAD, Calif., May 14, 2025 (GLOBE NEWSWIRE) -- Natural Alternatives International, Inc. ("NAI") (Nasdaq: NAII), a leading formulator, manufacturer, and marketer of customized nutritional supplements, today announced a net loss of $2.2 million, or $0.37 per diluted share, on net sales of $28.8 million for the third quarter of fiscal year 2025 compared to a net loss of $1.6 million, or $0.27 per diluted share, in the third quarter of the prior fiscal year. Net sales during the three months ended March 31, ...

Nasdaq: HWKN FISCAL 2025, QUARTER 4 Investor Presentation Published: May 14, 2025 FORWARD-LOOKING STATEMENTS The information contained in this presentation includes "forward-looking statements" which reflect management's expectations or beliefs as of the date of this presentation. Hawkins, Inc. cautions that actual future results could differ materially from the forward-looking statements in this presentation. Actual results may be affected by many important factors including risks and uncertainties identif ...